Ivosidenib vs azacitidine for IDH1-mutated MDS
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests if the drug ivosidenib alone or azacitidine alone can help people with a specific type of MDS that has an IDH1 mutation. It is for people who have not had strong MDS treatments yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with MDS (myelodysplastic syndromes) and have a specific change in a gene called IDH1 (R132 C, G, H, L, or S).
- You have not had any previous MDS treatments like hypomethylating agents (azacitidine), chemotherapy, or IDH inhibitors. (Some lower-risk patients can have had growth factors or luspatercept.)
- Your bone marrow has less than 20% blasts (immature cells). For lower-risk patients, blasts must be between 5% and 19%.
- The study is for people with moderate- to very-high-risk MDS, or lower-risk MDS that has low blood counts (low platelets, low neutrophils, or low hemoglobin).
- If your MDS is lower risk, you must have low blood counts and blasts between 5% and 19% to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
This trial tests whether adding ivosidenib to an oral chemotherapy pill (azacitidine) helps prevent relapse in adults over 55 who have a specific IDH1 gene mutation and whose acute myeloid leukemia is in remission after intensive chemo.
This trial studies ivosidenib together with azacitidine in people newly diagnosed with AML that has an IDH1 R132 gene mutation. It’s meant for patients who are not able to safely receive the strongest (intensive) chemotherapy, with the goal of improving control of the leukemia.
This trial tests a combination of three drugs (venetoclax, ivosidenib, and azacitidine) for people newly diagnosed with a specific type of AML that has an IDH1 mutation. The goal is to see if this mix works better than standard treatments.
This trial tests whether taking ivosidenib as a maintenance drug (to keep the cancer in remission) works better than standard care for patients with IDH1-mutated AML or high-risk MDS who cannot undergo a bone marrow transplant. Ivosidenib is a targeted drug that blocks a specific mutation found in your cancer.
Hear when a new Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.